HURA

TuHURA Biosciences

HURA

Market cap $103M

2.00 USD

-0.09

4.31%

At close Updated Nov 28, 4:00 PM EST

Pre-market

After hours

2.03

+0.03

1.5%

1 day

-4.31%

5 days

25%

1 month

-18.7%

3 months

-28.83%

6 months

-37.69%

Year to date

-51.34%

1 year

-69.51%

5 years

-99.92%

10 years

-100%

About: TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Employees: 19

Healthcare Biotechnology